2022, Volume 19, Issue 12
Engineering >> 2022, Volume 19, Issue 12 doi: 10.1016/j.eng.2021.09.014
Accurate Assessment and Tracking the Process of Liver-Specific Injury by the Residual Tissue Activity of Carboxylesterase 1 and Dipeptidyl Peptidase 4
a Center for Systems Pharmacokinetics, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
b Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China
c Shanghai Institute of Acupuncture and Meridian, Shanghai 200030, China
d School of Life and Pharmaceutical Sciences, Dalian University of Technology, Dalian 116024, China
# These authors contributed equally to this work.
Next Previous
Abstract
Accurately assessing and tracking the progression of liver-specific injury remains a major challenge in the field of biomarker research. Here, we took a retrospective validation approach built on the mutuality between serum and tissue biomarkers to characterize the liver-specific damage of bile duct cells caused by a-naphthyl isothiocyanate (ANIT). We found that carboxylesterase 1 (CES1), as an intrahepatic marker, and dipeptidyl peptidase 4 (DPP-IV), as an extrahepatic marker, can reflect the different pathophysiologies of liver injury. Levels of CES1 and DPP-IV can be used to identify liver damage itself and the inflammatory state, respectively. While the levels of the conventional serological biomarkers alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were all concomitantly elevated in serum and tissues after ANIT-induced injury, the levels of bile acids decreased in bile, increased in serum, and ascended in intrahepatic tissue. Although the level of γ-glutamyl transpeptidase (γ-GT) changed in an opposite direction, the duration was much shorter than that of CES1 and was quickly restored to normal levels. Therefore, among the abovementioned biomarkers, only CES1 made it possible to specifically determine whether the liver cells were destroyed or damaged without interference from inflammation. CES1 also enabled accurate assessment of the anti-cholestasis effects of ursodeoxycholic acid (UDCA; single component) and Qing Fei Pai Du Decoction (QFPDD; multicomponent). We found that both QFPDD and UDCA attenuated ANIT-induced liver damage. UDCA was more potent in promoting bile excretion but showed relatively weaker anti-injury and antiinflammatory effects than QFPDD, whereas QFPDD was more effective in blocking liver inflammation and repairing liver damage. Our data highlights the potential of the combined use of CES1 (as an intrahepatic marker of liver damage) and DPP-IV (as an extrahepatic marker of inflammation) for the accurate evaluation and tracking of liver-specific injury–an application that allows for the differentiation of liver damage and inflammatory liver injury.
Keywords
Carboxylesterase 1 ; Dipeptidyl peptidase 4 ; Liver injury ; Validation tracking
SupplementaryMaterials
Figures
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
References
[ 1 ] Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008;245(3):194–205. link1
[ 2 ] Den Bakker MA. Is histopathology still the gold standard? Ned Tijdschr Geneeskd 2017;160:D981. Dutch.
[ 3 ] Fu S, Wu D, Jiang W, Li J, Long J, Jia C, et al. Molecular biomarkers in druginduced liver injury: challenges and future perspectives. Front Pharmacol 2020;10:1667. link1
[ 4 ] Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24(8):971–83. link1
[ 5 ] Ferrigno A, Palladini G, Bianchi A, Rizzo V, Di Pasqua LG, Perlini S, et al. Lobespecific heterogeneity in asymmetric dimethylarginine and matrix metalloproteinase levels in a rat model of obstructive cholestasis. BioMed Res Int 2014;2014:1–8. link1
[ 6 ] Graham C, Chooniedass R, Stefura WP, Lotoski L, Lopez P, Befus AD, et al. Stability of pro- and anti-inflammatory immune biomarkers for human cohort studies. J Transl Med 2017;15(1):53. link1
[ 7 ] Na K, Lee EY, Lee HJ, Kim KY, Lee H, Jeong SK, et al. Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma. Proteomics 2009;9(16):3989–99. link1
[ 8 ] Perner F, Gyuris T, Rákóczy G, Sárváry E, Görög D, Szalay F, et al. Dipeptidyl peptidase activity of CD26 in serum and urine as a marker of cholestasis: experimental and clinical evidence. J Lab Clin Med 1999;134(1):56–67. link1
[ 9 ] Zou LW, Wang P, Qian XK, Feng L, Yu Y, Wang DD, et al. A highly specific ratiometric two-photon fluorescent probe to detect dipeptidyl peptidase IV in plasma and living systems. Biosens Bioelectron 2017;90:283–9. link1
[10] López-Riera M, Conde I, Castell JV, Jover R. A novel microRNA signature for cholestatic drugs in human hepatocytes and its translation into novel circulating biomarkers for drug-induced liver injury patients. Toxicol Sci 2020;173(2):229–43. link1
[11] Imai T, Taketani M, Shii M, Hosokawa M, Chiba K. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab Dispos 2006;34(10):1734–41. link1
[12] Wang DD, Zou LW, Jin Q, Guan XQ, Yu Y, Zhu YD, et al. Bioluminescent sensor reveals that carboxylesterase 1a is a novel endoplasmic reticulumderived serologic indicator for hepatocyte injury. ACS Sens 2020;5 (7):1987–95. link1
[13] Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020;5(5):428–30. link1
[14] Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020;26(7):1017–32. link1
[15] Sivandzadeh GR, Askari H, Safarpour AR, Ejtehadi F, Raeis-Abdollahi E, Vaez Lari A, et al. COVID-19 infection and liver injury: clinical features, biomarkers, potential mechanisms, treatment, and management challenges. World J Clin Cases 2021;9(22):6178–200. link1
[16] Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver int 2020;40(5):998–1004. link1
[17] Deng ML, Chen YJ, Yang ML, Liu YW, Chen H, Tang XQ, et al. COVID-19 combined with liver injury: current challenges and management. World J Clin Cases 2021;9(15):3487–97. link1
[18] Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: abnormal liver function tests. J Hepatol 2020;73(3):566–74. link1
[19] Maremanda KP, Sundar IK, Li D, Rahman I. Age-dependent assessment of genes involved in cellular senescence, telomere, and mitochondrial pathways in human lung tissue of smokers, COPD, and IPF: associations with SARS-CoV-2 COVID-19 ACE2–TMPRSS2–Furin–DPP4 axis. Front Pharmacol 2020;11:584637. link1
[20] Bassendine MF, Bridge SH, McCaughan GW, Gorrell MD. COVID-19 and comorbidities: a role for dipeptidyl peptidase 4 (DPP4) in disease severity? J Diabetes 2020;12(9):649–58. link1
[21] Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol 2020;57(7):779–83. link1
[22] Zhong LLD, Lam WC, Yang W, Chan KW, Sze SCW, Miao J, et al. Potential targets for treatment of coronavirus disease 2019 (COVID-19): a review of Qing-FeiPai-Du-Tang and its major herbs. Am J Chin Med 2020;48(05):1051–71. link1
[23] Xu F, Hou T, Shen A, Jin H, Xiao Y, Yu W, et al. Mechanism deconvolution of Qing Fei Pai Du decoction for treatment of coronavirus disease 2019 (COVID19) by label-free integrative pharmacology assays. J Ethnopharmacol 2021;280:114488. link1
[24] Wu XV, Dong Y, Chi Y, Yu M, Wang W. Traditional Chinese medicine as a complementary therapy in combat with COVID-19—a review of evidencebased research and clinical practice. J Adv Nurs 2021;77(4):1635–44. link1
[25] Xu X, Xia J, Zhao S, Wang Q, Ge G, Xu F, et al. Qing-Fei-Pai-Du decoction and wogonoside exert anti-inflammatory action through down-regulating USP14 to promote the degradation of activating transcription factor 2. FASEB J 2021;35(9):e21870. link1
[26] Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology 2011;53(4):1377–87. link1
[27] Dietrich CG, Ottenhoff R, de Waart DR, Oude Elferink RP. Role of MRP2 and GSH in intrahepatic cycling of toxins. Toxicology 2001;167(1):73–81. link1
[28] Kossor DC, Goldstein RS, Ngo W, DeNicola DB, Leonard TB, Dulik DM, et al. Biliary epithelial cell proliferation following alpha-naphthylisothiocyanate (ANIT) treatment: relationship to bile duct obstruction. Fundam Appl Toxicol 1995;26(1):51–62. link1
[29] Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012;56(5):1751–9. link1
[30] Cullen JM, Faiola B, Melich DH, Peterson RA, Jordan HL, Kimbrough CL, et al. Acute a-naphthylisothiocyanate-induced liver toxicity in germfree and conventional male rats. Toxicol Pathol 2016;44(7):987–97. link1
[31] Xie G, Wang X, Huang F, Zhao A, Chen W, Yan J, et al. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer 2016;139 (8):1764–75. link1
[32] Xie G, Wang Y, Wang X, Zhao A, Chen T, Ni Y, et al. Profiling of serum bile acids in a healthy Chinese population using UPLC-MS/MS. J Proteome Res 2015;14 (2):850–9. link1
[33] Maronpot RR, Yoshizawa K, Nyska A, Harada T, Flake G, Mueller G, et al. Hepatic enzyme induction histopathology. Toxicol Pathol 2010;38(5):776–95. link1
[34] Tu C, Gao Y, Song D, Niu M, Ma R, Zhou M, et al. Screening for susceptibilityrelated biomarkers of diclofenac-induced liver injury in rats using metabolomics. Front Pharmacol 2021;12:693928. link1
[35] Apica BS, Lee WM. Drug-induced liver injury. Pathobiol Hum Dis 2014;127 (6):1825–37. link1
[36] Her L, Zhu HJ. Carboxylesterase 1 and precision pharmacotherapy: pharmacogenetics and nongenetic regulators. Drug Metab Dispos 2020;48 (3):230–44. link1
[37] Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, et al. Effects of shosaiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999;29(1):149–60. link1
[38] Zhou YX, Qiu YQ, Xu LQ, Guo J, Li LJ. Xiao-Chai-Hu Tang in treating model mice with D-galactosamine-induced liver injury. Afr J Tradit Complement Altern Med 2012;9(3):405–11. link1
[39] Takahashi Y, Soejima Y, Kumagai A, Watanabe M, Uozaki H, Fukusato T, et al. Inhibitory effects of Japanese herbal medicines sho-saiko-to and juzen-taihoto on nonalcoholic steatohepatitis in mice. PLoS ONE 2014;9(1):e87279. link1
[40] Chen MH, Chen JC, Tsai CC, Wang WC, Chang DC, Lin CC, et al. Sho-saiko-to prevents liver fibrosis induced by bile duct ligation in rats. Am J Chin Med 2004;32(2):195–207. link1
[41] Wang H, Fang ZZ, Meng R, Cao YF, Tanaka N, Krausz KW, et al. Glycyrrhizin and glycyrrhetinic acid inhibits alpha-naphthyl isothiocyanate-induced liver injury and bile acid cycle disruption. Toxicology 2017;386:133–42. link1
[42] Röhrl C, Eigner K, Fruhwürth S, Stangl H, Kanzaki M. Bile acids reduce endocytosis of high-density lipoprotein (HDL) in HepG2 cells. PLoS ONE 2014;9(7):e102026. link1
[43] Oizumi K, Sekine S, Fukagai M, Susukida T, Ito K. Identification of bile acids responsible for inhibiting the bile salt export pump, leading to bile acid accumulation and cell toxicity in rat hepatocytes. J Pharm Sci 2017;106 (9):2412–9. link1
京公网安备 11010502051620号
